特一藥業(002728.SZ)第三季度預盈2394.64萬-3113.92萬元 同比增長1634%-2155%
格隆匯10月13日丨特一藥業(002728.SZ)公佈,預計2021年前三季度歸屬於上市公司股東的淨利潤9926.06萬元-10645.34萬元,同比增長245%-270%;其中,第三季度歸屬於上市公司股東的淨利潤2394.64萬-3113.92萬元,同比增長1634%-2155%。
報吿期內,歸屬於上市公司股東的淨利潤較上年同期實現較大增長,主要原因為:公司業務基本恢復至正常水平,銷售收入特別是核心產品“特一”牌止咳寶片的銷售恢復較好;同時,公司不斷加強品牌建設、優化產品結構,加大內部管理,堅持降本增效,在報吿期內取得了較好效果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.